CD274 and neoplasm: Since PD-L1 expression level, MMR status, and other biomarkers that are recommended by the guidelines are invasive and cannot be tracked dynamically, new blood biomarkers such circulating tumor cells and neutrophil-to-lymphocyte ratio (NLR) have been identified.